FDA Panel Reluctantly Backs Patisiran for ATTR Cardiomyopathy

(MedPage Today) -- FDA advisors conceded on Wednesday that the benefit-risk balance of patisiran (Onpattro) technically checks out in wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM, also known as cardiac ATTR amyloidosis...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news